Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Price History  |  Ratios  |  Insiders

Breaking & Recent News Trevena Inc (EM) TRVN

Healthcare Biotechnology
Trevena, Inc., a biopharmaceutical company, focuses on the development and commercialization of novel medicines for patients affected by central nervous system disorders. Its lead product candidates include OLINVYK (Oliceridine) injection, a G protein biased mu-opioid receptor (MOR) ligand for the management of moderate-to-severe acute pain; TRV734, a small molecule G protein biased ligand of... see more

Recent & Breaking News (EXPM:TRVN)

Trevena Reports Third Quarter 2024 Results and Provides Business Update

GlobeNewswire November 7, 2024

Trevena Announces Receipt of Nasdaq Delisting Notification

GlobeNewswire October 4, 2024

Trevena Announces Reverse Stock Split

GlobeNewswire August 8, 2024

Trevena Reports Second Quarter 2024 Results and Provides Business Update

GlobeNewswire August 8, 2024

Sagimet Biosciences Announces Appointment of Anne Phillips and Jennifer Jarrett to its Board of Directors

GlobeNewswire August 1, 2024

Trevena Announces $2M Non-Dilutive Financing Tranche and Reduction in Outstanding Liabilities in Connection with Existing ex-US Royalty Financing

GlobeNewswire July 8, 2024

Trevena Announces Preclinical TRV045 Data Providing Insight Into Novel Mechanism of Analgesic Effect in Chronic Neuropathic Pain Model and Demonstrating Statistically Significant Anti-Seizure Activity in Epilepsy Models

GlobeNewswire June 20, 2024

Trevena Reports First Quarter 2024 Results and Provides Business Update

GlobeNewswire May 15, 2024

Trevena Reports Fourth Quarter 2023 Results and Provides Corporate Update

GlobeNewswire April 1, 2024

Trevena Announces the Closing of $4 Million Concurrent Private Placement and Warrant Exercise

GlobeNewswire December 28, 2023

Trevena Inc. Announces $4 Million Concurrent Private Placement and Warrant Exercise

GlobeNewswire December 27, 2023

Trevena Announces TRV045 Presentation at the American College of Neuropsychopharmacology 62nd Annual Meeting

GlobeNewswire December 4, 2023

Trevena Awarded OLINVYK Agreement with Premier, Inc.

GlobeNewswire December 4, 2023

Trevena Announces Acceptance of Abstract Examining the Use of OLINVYK in Patients with Acute Burn Injuries

GlobeNewswire November 30, 2023

Trevena Reports Third Quarter 2023 Results and Provides Business Update

GlobeNewswire November 14, 2023

Trevena to Release Third Quarter 2023 Financial Results on November 14, 2023

GlobeNewswire November 9, 2023

Trevena Reports Favorable TRV045 Topline Safety and Tolerability Data from Proof-of-Concept Studies

GlobeNewswire October 16, 2023

Trevena Announces Completion of Initial Analysis of OLINVYK Continuous Respiratory Monitoring Data from VOLITION Study and Presentation at American Society of Anesthesiologists Conference

GlobeNewswire October 2, 2023

Trevena Announces Receipt of $15 Million Non-Dilutive Tranche and Provides General Business Update

GlobeNewswire September 6, 2023

Trevena Announces Preliminary TRV045 Data from Two Proof-of-Concept Studies Evaluating S1PR Mechanism of Action and CNS Target Engagement

GlobeNewswire September 6, 2023

Podcasts